Features in 2016

Chasing treatments and gouging patients in a bloated, capitalist healthcare system.

A discussion of some of the challenges and promise of single-cell technology.

Interest in cancer vaccines is being reignited by a greater understanding of tumor immunology and the potential of combining immunogens with new breakthrough immunotherapies.

Last year witnessed the biotech sector's first retreat from a multi-year run of incredible performance on the public markets.

Nature Biotechnology asks representatives from three different cancer 'moonshot' initiatives to outline their visions.

The eagerness of non-traditional biotech investors made for another good year for the industry. Will it continue?

With an approval likely at the EMA, ex vivo gene therapy in hematopoietic stem cells appears poised for prime time.

Immuno-oncology was hotly pursued by investors in 2015, along with drug delivery platforms. In the agbiotech world, a systems biology company set up shop.

Current regulatory regimes for genetically engineered crops fail to use a scientifically defensible approach or tailor the degree of regulatory review to the level of actual hazard or risk. We describe a rational way forward.

Authors of some of the most highly cited Nature Biotechnology nonbiomedical papers from the past 20 years discuss their work and challenges for their fields.

Authors of some of the most highly cited Nature Biotechnology papers that describe research tools discuss their work and challenges for their fields.

Authors of some of the most highly cited Nature Biotechnology biomedical papers from the past 20 years discuss their work and challenges for their fields.

A selection of individuals from the biotech ecosystem give their views on the challenges facing the sector over the coming years.

US biotech sector revenue is estimated to have grown on average >10% each year over the past decade—much faster than the rest of the economy. A more comprehensive assessment of biotech's economic contribution, however, will require improved data collection, classification and analysis.

Nature Biotechnology asks a selection of researchers about the most exciting frontier in their field and the most needed technologies for advancing knowledge and applications.

A look at 20 years of the dark side of biotech.

Although a few arable crops and agronomic traits will likely dominate commercial varieties for the foreseeable future, with many being stacked together, more quality traits and specialty crops are being introduced into the pipeline.